【24h】

Treatment and management of acute venous thromboembolic disease.

机译:急性静脉血栓栓塞性疾病的治疗和管理。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Venous thromboembolic (VTE) disease consists of deep vein thrombosis and/or pulmonary embolism. Either low molecular weight heparin given subcutaneously or unfractionated heparin administered intravenously are used for the initial treatment. Simultaneously, warfarin therapy is initiated. Thrombolytic therapy plays a limited role. Following the initial heparin treatment, anticoagulation clinics provide an excellent means of monitoring the oral anticoagulation. Patient education is important and patients should be well versed in the basic features of oral anticoagulation. The duration of oral anticoagulation is dependent on a number of factors including the presence of inherited risk factors, bleeding risk and patient reliability. Residual thrombus in the affected vein may indicate the need for prolonged anticoagulation. The low intensity oral anticoagulation (INR 1.5-2.0) is useful in preventing recurrent thrombosis following the initial treatment period with full intensity oral anticoagulation.
机译:静脉血栓栓塞症(VTE)疾病包括深静脉血栓形成和/或肺栓塞。皮下给予的低分子量肝素或静脉内给予的普通肝素均用于初始治疗。同时,开始进行华法林治疗。溶栓治疗作用有限。在最初的肝素治疗之后,抗凝诊所为监测口服抗凝提供了极好的方法。对患者的教育很重要,患者应该精通口服抗凝的基本功能。口服抗凝药的持续时间取决于许多因素,包括遗传性危险因素的存在,出血风险和患者可靠性。受影响的静脉中残留血栓可能表明需要长期抗凝。低强度口服抗凝药(INR 1.5-2.0)可用于预防在初期治疗后以全强度口服抗凝药复发的血栓形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号